INSY Insider Trading Activity and SEC Form 4 Filings
INSY insider trading summary
No open-market insider purchases or sales of Insys Therapeutics, Inc. (INSY) have been reported on SEC Form 4 in the past 12 months.
Latest INSY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 10, 2018 | Brian Tambi | Director | Sell | $1.1M (166,504 @ $6.41) |
| Aug 11, 2017 | John N Kapoor Trust Dated September 20 1989 | 10% Owner | Buy | $156K (17,500 @ $8.93) |
| Aug 11, 2017 | John N Kapoor | Director | Buy | $156K (17,500 @ $8.93) |
| Aug 10, 2017 | Saeed Motahari | President & CEO | Buy | $49K (5,500 @ $8.92) |
| Jun 14, 2017 | Saeed Motahari | President & CEO | Buy | $60K (5,400 @ $11.10) |
| Jun 1, 2017 | Rohit Vishnoi | Director | Buy | $57K (4,000 @ $14.14) |
| May 18, 2017 | Steven J Meyer | Director | Buy | $98K (8,000 @ $12.21) |
| May 16, 2017 | Saeed Motahari | President & CEO | Buy | $54K (4,500 @ $11.98) |
| Nov 4, 2016 | Steven J Meyer | Director | Buy | $107K (10,000 @ $10.75) |
| Aug 16, 2016 | Theodore H Stanley | Director | Sell | $270K (15,000 @ $18.02) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.